• Fig A shows a schematic representation

  2023-12-22

  

  Fig. 2A shows a schematic representation of histological results according to the Franklin and Paxinos Mouse Brain Atlas (2001). The black circles represent the sites of drug infusion that were on-target within the amygdala. Gray circles represent the animals that had infusion locations outside the

• Consistent with the observation that mutations in

  2023-12-22

  

  Consistent with the observation that mutations in the redox-partner binding site of P450c17 that reverse charge from basic to acidic (R347H, R358Q) cause 17,20-lyase deficiency (Geller et al, 1997, Geller et al, 1999), at least one POR mutation that changes a residue in the FMN domain from neutral t

• Cy5.5 NHS ester br Dual role of autophagy

  2023-12-22

  

  Dual role of autophagy in human diseases Emerging evidence suggests that autophagy serves as a double-edged sword in several human diseases, such as CNS diseases (Rubinsztein et al., 2015), arteriosclerosis (Schrijvers et al., 2011) and cancer (Ozpolat and Benbrook, 2015). Likewise, currently the

• br Current limitations and future directions There are

  2023-12-22

  

  Current limitations and future directions There are several limitations associated with PET imaging of aromatase using carbon-11 labeled aromatase inhibitors. Due to the very short half-life of carbon 11 (20min), PET studies with currently available, validated tracers can only be performed in med

• However one should keep in mind that these results

  2023-12-21

  

  However, one should keep in mind that these results may not reflect exactly in vivo antioxidant activity. Many other issues such as absorption, metabolism and physicochemical properties of different antioxidants must also be considered (Prior et al., 2007, Wu et al., 2004). Some research groups are

• br Declarations Funding None for the

  2023-12-21

  

  Declarations Funding: None for the paper in question. Competing interests: Florent Morio has received speaker's fees from Gilead, Basilea, and MSD and travel grants from Gilead, MSD, Pfizer, Basilea, and Astellas. Ethical approval: Not relevant for the paper in question. Introduction Lactic

• At Johns Hopkins Aramco Health JHAH we started an ASP

  2023-12-21

  

  At Johns Hopkins Aramco Health (JHAH), we started an ASP in 2011 with an educational program of physicians and pharmacist. The program was enhanced mid-2012 with the following interventions: a re-designed antibiotic sensitivity report [2], intravenous to oral conversion program, vancomycin pharmacok

• Sorafenib was the first small RTK inhibitor drug

  2023-12-21

  

  Sorafenib was the first small RTK inhibitor drug to be developed and was initially approved against renal cell carcinoma, then against hepatocellular carcinoma (HCC) and more recently for differentiated thyroid treatment [111]. Sunitinib soon followed, being approved for gastrointestinal stromal tum

• Maynard et al demonstrated that serum levels

  2023-12-21

  

  Maynard et al. [54] demonstrated that serum levels of sFlt-1 were five times higher in pregnant women with PE than in normotensive women; as a consequence, VEGF and PlGF levels were found to be proportionally reduced in these women [54]. The literature confirms that there is a sharp increase in sFlt

• Methyllycaconitine citrate receptor Based on the general str

  2023-12-21

  

  Based on the general structure-function principle in biology [[19], [20], [21]], toxic oligomers are expected to have well-defined three-dimensional structures to carry out their pathological functions. A common amyloid toxicity mechanism also suggests that toxic oligomers of different amyloid prote

• The increased occurrence of ARIA E in APOE

  2023-12-21

  

  The increased occurrence of ARIA-E in APOE ε4 carriers in phase 2 studies resulted in separate protocols for carriers and noncarriers in the subsequent phase 3 studies. Two 18-month trials comprising 1121 carriers and 1331 noncarriers with mild to moderate AD tested doses of bapineuzumab that varied

• Interestingly we noticed that LPS exposure was associated wi

  2023-12-21

  

  Interestingly, we noticed that LPS exposure was associated with decreased phosphorylation of AMPK and increased phosphorylation of p70S6K1, suggesting that AMPK inactivation and the subsequent mTOR activation might be involved in the development of LPS-induced inflammation. On the other side, treatm

• br Conclusion br Introduction The identification

  2023-12-21

  

  Conclusion Introduction The identification of Alzheimer's disease (AD) biomarkers and their ability to measure pathology antemortem has led to a fundamental reconsideration of the pathogenesis of AD. The importance of biomarkers was already reflected in revised diagnostic criteria proposed by

• br Conclusions br Acknowledgments This research was funded b

  2023-12-21

  

  Conclusions Acknowledgments This research was funded by the National Science Foundation Committee (NSFC) of China (Nos. 81171058 and 81471146) and Capital Development Scientific Research in China (Nos. 2011-5001-04 and 2014-4-5013). We are grateful for all of the participants who donated blood

• Fmoc-Val-OH receptor To our knowledge BAY has

  2023-12-21

  

  To our knowledge, BAY 60-6583 has not progressed to clinical development and remains to be the only ADORA2B agonist that has been developed.33, 34 Further development of similar compounds would be beneficial in future fibrosis research. One of the limitations of our study is being limited to in vit

16062 records 222/1071 page Previous Next First page 上5页 221222223224225 下5页 Last page